We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+0.74%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$138M
AUM Growth
-$2.5M
Cap. Flow
-$444K
Cap. Flow %
-0.32%
Top 10 Hldgs %
90.14%
Holding
46
New
6
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$316K
2
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$164K
3
MCRB icon
Seres Therapeutics
MCRB
+$147K
4
ALDR
Alder Biopharmaceuticals
ALDR
+$139K
5
WKHS icon
Workhorse Group
WKHS
+$118K

Top Sells

Rank Stock Value
1
COLL icon
Collegium Pharmaceutical
COLL
+$1.39M
2
KURA icon
Kura Oncology
KURA
+$62.2K

Sector Composition

Rank Sector Weight
1 Healthcare 91.54%
2 Energy 3.85%
3 Consumer Staples 1.23%
4 Consumer Discretionary 0.07%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$76.8M 55.78%
779,051
– –
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$31.3M 22.73%
217,580
– –
EQT icon
3
EQT Corp
EQT
$31B
$3.27M 2.38%
77,705
– –
VRML
4
DELISTED
Vermillion, Inc.
VRML
$3.02M 2.19%
2,717,514
– –
HNSN
5
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$2.1M 1.52%
528,142
– –
MASI
6
DELISTED
Masimo
MASI
$1.92M 1.4%
36,600
– –
YTEN
7
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$1.69M 1.23%
236
– –
BIOL
8
DELISTED
Biolase, Inc.
BIOL
$1.5M 1.09%
103
– –
CFRX
9
DELISTED
ContraFect Corporation
CFRX
$1.37M 1%
594
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$17.2B
$1.15M 0.83%
25,200
– –
MDVN
11
DELISTED
MEDIVATION, INC.
MDVN
$1.13M 0.82%
18,760
– –
OVV icon
12
Ovintiv
OVV
$16.2B
$1.03M 0.75%
26,460
– –
OMED
13
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$870K 0.63%
70,689
– –
MRK icon
14
Merck
MRK
$315B
$864K 0.63%
15,720
– –
TSRO
15
DELISTED
TESARO, Inc.
TSRO
$710K 0.52%
8,450
+1,500
+22% +$66.9K
QDEL icon
16
QuidelOrtho
QDEL
$1.19B
$696K 0.51%
38,975
– –
NXTM
17
DELISTED
NxStage Medical Inc.
NXTM
$611K 0.44%
28,200
– –
CTRA
18
DELISTED
Coterra Energy
CTRA
$541K 0.39%
21,000
– –
WMGI
19
DELISTED
Wright Medical Group Inc
WMGI
$521K 0.38%
30,000
– –
OXFD
20
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$507K 0.37%
56,303
– –
ARAY icon
21
Accuray
ARAY
$30.8M
$495K 0.36%
95,300
– –
PXD
22
DELISTED
Pioneer Natural Resource Co.
PXD
$456K 0.33%
3,000
– –
QTNT
23
DELISTED
Quotient Limited Ordinary Shares
QTNT
$451K 0.33%
1,455
– –
CORT icon
24
Corcept Therapeutics
CORT
$9.72B
$437K 0.32%
80,000
– –
SIEN
25
DELISTED
Sientra, Inc.
SIEN
$417K 0.3%
6,330
– –
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Birchview Capital held 46 positions worth $138M, down 1.8% from $140M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Birchview Capital's Q2 2016 filing shows 6 new, 1 increased, 1 reduced and 1 closed positions. Its largest new stake was RELYPSA INC COM: 18,000 shares worth $333K. The largest sale was Collegium Pharmaceutical, an estimated $1.39M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q2 2016 buy was RELYPSA INC COM: 18,000 shares worth $333K.
  • Birchview Capital added most to TESARO, Inc. in Q2 2016, an estimated $66.9K increase.
  • Birchview Capital's biggest Q2 2016 reduction was Kura Oncology, cutting an estimated $62.2K.
  • Birchview Capital fully exited Collegium Pharmaceutical in Q2 2016, selling an estimated $1.39M.
  • Birchview Capital's ten largest holdings make up 90% of its $138M portfolio in Q2 2016.
  • Birchview Capital opened 6 new positions and closed 1 in Q2 2016.
  • Birchview Capital's portfolio value fell 1.8% quarter-over-quarter to $138M.

Based on Birchview Capital's 13F filing for Q2 2016, filed 9 Aug 2016.